Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal

27 de agosto de 2026 actualizado por: Johnson & Johnson Vision Care, Inc.
This study is a 4-visit, multi-site, prospective, controlled, randomized, single-masked (subjects), two-arm parallel group, bilateral, dispensing clinical trial to compare the performance of the Test lens to the Control lens in terms of safety and efficacy.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

150

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Study Contact
  • Número de teléfono: 1-800-843-2020
  • Correo electrónico: tkarkkai@its.jnj.com

Ubicaciones de estudio

  • Estados Unidos
    • Florida
      • Longwood, Florida, Estados Unidos, 32779
        • Pearson Research Center PA
    • Georgia
      • Roswell, Georgia, Estados Unidos, 30076
        • VisualEyes
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63144
        • The Koetting Associates
    • New York
      • Jamestown, New York, Estados Unidos, 14701
        • Spectrum Eyecare
      • Manhattan, New York, Estados Unidos, 10022
        • Center for Ophthalmic and Vision Research/Eye Associates of New York
      • Vestal, New York, Estados Unidos, 13850
        • Sacco Eye Group
    • Rhode Island
      • Warwick, Rhode Island, Estados Unidos, 02888
        • Dr. David W. Ferris & Associates
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38119
        • Total Eye Care
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Paradigm Research Center, LLC
      • Tyler, Texas, Estados Unidos, 75703
        • Tyler Eye Associates
    • Virginia
      • Salem, Virginia, Estados Unidos, 24153
        • Botetourt Eyecare, LLC

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

  1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  3. Be at least 40 years of age and not greater than 70 years of age at the time of consent.
  4. Own a wearable pair of spectacles if required for their distance vision.
  5. Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 30 days or more duration).
  6. Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
  7. The subject's distance spherical equivalent refraction (vertex corrected if ≥-4.25 D) must be in the range of -1.50 D to -5.50 D in each eye.
  8. The subject's refractive cylinder must be ≤0.75 D in each eye.
  9. The subject's ADD power must be in the range of +0.75 D to +2.50 D.
  10. The subject must have distance best corrected visual acuity of 0.0 logMAR (20/20 Snellen, 5.0 on the China standard 5-point logMAR visual acuity scale) or better in each eye.

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Be currently pregnant or lactating.
  2. Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
  3. Have been diagnosed with diabetes.
  4. Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
  5. Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.).
  6. Have a history of amblyopia, strabismus or binocular vision abnormality.
  7. Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids.
  8. Use of any ocular medication.
  9. Have a history of herpetic keratitis.
  10. Have a history of irregular cornea.
  11. Have a history of pathological dry eye.
  12. Have a history of glaucoma or glaucoma suspect.
  13. Have a history of any retinal disease/condition that may interfere with any of the study assessments or are not stable and have potential to progress during the study.
  14. Have participated in any contact lens or lens care product clinical trial within 15 days prior to study enrollment.
  15. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild, sibling of the employee or their spouse) of the clinical site.
  16. Have any known hypersensitivity or allergic reaction to sodium fluorescein.
  17. Have Grade 3 or greater palpebral conjunctival observations or Grade 2 or greater slit lamp findings (e.g. corneal edema, corneal vascularization, corneal staining, bulbar injection, etc.) on the ISO 11980 classification scale, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
  18. Have any current ocular infection or inflammation.
  19. Have intraocular pressure in one or both eyes >21mmHg
  20. Have signs of any retinal disease/conditions that may interfere with any of the study assessments or are not stable and have potential to progress during the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Senofilcon A
Eligible subjects will be randomized to the Senofilcon A Lens for the duration of the study.
Dispositivo: Senofilcon A
ACUVUE® Oasys MAX 1-Day Multifocal
Comparador activo: Nelfilcon A
Eligible subjects will be randomized to the Nelfilcon A Lens for the duration of the study.
Dispositivo: Nelfilcon A
DAILIES® AquaComfort Plus® Multifocal

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean binocular HLHC distance Visual Acuity
Periodo de tiempo: At 1-week follow-up
Mean binocular HLHC VA at distance (4m)
At 1-week follow-up
Mean binocular HLHC Intermediate Visual Acuity
Periodo de tiempo: At 1-week follow-up
Mean binocular HLHC VA at Intermediate (64cm)
At 1-week follow-up
Mean binocular HLHC Near Visual Acuity
Periodo de tiempo: At 1-week follow-up
Mean binocular HLHC VA at Near (40cm)
At 1-week follow-up
Incidence rate of study-lens related (i.e. related and possibly related) ocular adverse events.
Periodo de tiempo: Up to 1-month follow-up
Up to 1-month follow-up

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean binocular HLHC distance Visual Acuity
Periodo de tiempo: At 1-month follow-up
Mean binocular HLHC VA at distance (4m)
At 1-month follow-up
Mean binocular HLHC Intermediate Visual Acuity
Periodo de tiempo: At 1-month follow-up
Mean binocular HLHC VA at Intermediate (64cm)
At 1-month follow-up
Mean binocular HLHC Near Visual Acuity
Periodo de tiempo: At 1-month follow-up
Mean binocular HLHC VA at Near (40cm)
At 1-month follow-up
Incidence rate of Slit Lamp Findings (SLF)
Periodo de tiempo: Up to 1-month follow-up
Slit lamp findings will be assessed for each eye at all study visits (scheduled and unscheduled) by grade. SLFs will be evaluated and graded using the ISO 11980 Grading scale from 0 to 4, where Grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e., Grade 1 = trace, Grade 2 = mild, Grade 3 = moderate and Grade 4 = severe).
Up to 1-month follow-up

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Johnson & Johnson Vision Care, Inc.

Investigadores

  • Director de estudio: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

28 de agosto de 2026

Finalización primaria (Estimado)

11 de diciembre de 2026

Finalización del estudio (Estimado)

11 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

23 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de agosto de 2026

Publicado por primera vez (Actual)

26 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CR-6560

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir